Removal of Aβ Oligomers from the Blood: A Potential Therapeutic System for Alzheimer’s Disease
Yuta Saito, 1–3 Miwa Sakata, 3 Moe Kobayakawa, 3 Hiroshi Kawachi, 4 Kazunori Kawaguchi, 3 Yoshiyuki Hiki, 3 Masao Kato, 1 Mayuko Mori, 1, 3 Midori Hasegawa, 1 Norimi Ohashi, 4 Yukio Yuzawa, 1 Nobuya Kitaguchi 3 1Department of Nephrology, School of Medicine, Fujita Health University, Toyoa...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/06a560a2c9e14525a9e3896d39fab4c2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:06a560a2c9e14525a9e3896d39fab4c2 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:06a560a2c9e14525a9e3896d39fab4c22021-12-02T08:54:42ZRemoval of Aβ Oligomers from the Blood: A Potential Therapeutic System for Alzheimer’s Disease1178-2021https://doaj.org/article/06a560a2c9e14525a9e3896d39fab4c22020-03-01T00:00:00Zhttps://www.dovepress.com/removal-of-abeta-oligomers-from-the-blood-a-potential-therapeutic-syst-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Yuta Saito, 1–3 Miwa Sakata, 3 Moe Kobayakawa, 3 Hiroshi Kawachi, 4 Kazunori Kawaguchi, 3 Yoshiyuki Hiki, 3 Masao Kato, 1 Mayuko Mori, 1, 3 Midori Hasegawa, 1 Norimi Ohashi, 4 Yukio Yuzawa, 1 Nobuya Kitaguchi 3 1Department of Nephrology, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan; 2Graduate School of Medical Sciences, Fujita Health University, Toyoake, Aichi, Japan; 3Faculty of Clinical Engineering, School of Medical Sciences, Fujita Health University, Toyoake, Aichi, Japan; 4Ogaki Municipal Hospital, Ogaki, Gifu, JapanCorrespondence: Nobuya Kitaguchi 4-8-17, Yuzato, Higashisumiyosi-ku, Osaka 546-0013, JapanTel/Fax +81-6-3-4392-7087Email nkitaguc@fujita-hu.ac.jpPurpose: Amyloid-β protein (Aβ) is one of the causative proteins of Alzheimer’s disease. We have been developing extracorporeal blood Aβ-removal systems as a method for enhancing Aβ clearance from the brain. We reported previously that medical adsorbents and hemodialyzers removed Aβ monomers from peripheral blood, which was associated with influx of Aβ monomers from the brain into the bloodstream. Our intent here was to develop a method to promote clearance of Aβ oligomers and to provide an estimate of the molecular size of intact Aβ oligomers in plasma.Methods: Two hollow-fiber devices with different pore sizes (Membranes A and B) were evaluated as removers of Aβ oligomers with human plasma in vitro. The concomitant removal of Aβ oligomers and monomers was investigated by using Membrane B and hexadecyl alkylated cellulose beads or polysulfone hemodialyzers. Double-filtration plasmapheresis with Membrane A was investigated as an approach for the removal of plasma Aβ oligomers in humans.Results: Aβ oligomers were effectively removed by both Membranes A and B. The increase of Aβ oligomers in plasma was observed just after the removal of plasma Aβ oligomers in humans. The intact molecular size of major Aβ oligomers in the plasma was estimated to be larger than albumin at approximately 60 kDa or more. Additionally, the concomitant removal of Aβ monomers and oligomers evoked dissociation of larger Aβ oligomers into smaller ones and monomers.Conclusion: Aβ oligomers were cleared from plasma both in vitro and in human subjects by using hollow-fiber membranes with large pores, indicating that their intact sizes were mostly larger than 60 kDa. Aβ oligomers in peripheral circulation were increased after some clearances in human. Further investigation will determine whether the Aβ oligomers detected in circulation after clearance were via influx from the brain.Keywords: Aβ, amyloid beta, oligomer, Alzheimer’s disease, blood purification, membrane separationSaito YSakata MKobayakawa MKawachi HKawaguchi KHiki YKato MMori MHasegawa MOhashi NYuzawa YKitaguchi NDove Medical Pressarticleaβamyloid betaoligomeralzheimer’s diseaseblood purificationmembrane separationNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 16, Pp 607-627 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
aβ amyloid beta oligomer alzheimer’s disease blood purification membrane separation Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
aβ amyloid beta oligomer alzheimer’s disease blood purification membrane separation Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Saito Y Sakata M Kobayakawa M Kawachi H Kawaguchi K Hiki Y Kato M Mori M Hasegawa M Ohashi N Yuzawa Y Kitaguchi N Removal of Aβ Oligomers from the Blood: A Potential Therapeutic System for Alzheimer’s Disease |
| description |
Yuta Saito, 1–3 Miwa Sakata, 3 Moe Kobayakawa, 3 Hiroshi Kawachi, 4 Kazunori Kawaguchi, 3 Yoshiyuki Hiki, 3 Masao Kato, 1 Mayuko Mori, 1, 3 Midori Hasegawa, 1 Norimi Ohashi, 4 Yukio Yuzawa, 1 Nobuya Kitaguchi 3 1Department of Nephrology, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan; 2Graduate School of Medical Sciences, Fujita Health University, Toyoake, Aichi, Japan; 3Faculty of Clinical Engineering, School of Medical Sciences, Fujita Health University, Toyoake, Aichi, Japan; 4Ogaki Municipal Hospital, Ogaki, Gifu, JapanCorrespondence: Nobuya Kitaguchi 4-8-17, Yuzato, Higashisumiyosi-ku, Osaka 546-0013, JapanTel/Fax +81-6-3-4392-7087Email nkitaguc@fujita-hu.ac.jpPurpose: Amyloid-β protein (Aβ) is one of the causative proteins of Alzheimer’s disease. We have been developing extracorporeal blood Aβ-removal systems as a method for enhancing Aβ clearance from the brain. We reported previously that medical adsorbents and hemodialyzers removed Aβ monomers from peripheral blood, which was associated with influx of Aβ monomers from the brain into the bloodstream. Our intent here was to develop a method to promote clearance of Aβ oligomers and to provide an estimate of the molecular size of intact Aβ oligomers in plasma.Methods: Two hollow-fiber devices with different pore sizes (Membranes A and B) were evaluated as removers of Aβ oligomers with human plasma in vitro. The concomitant removal of Aβ oligomers and monomers was investigated by using Membrane B and hexadecyl alkylated cellulose beads or polysulfone hemodialyzers. Double-filtration plasmapheresis with Membrane A was investigated as an approach for the removal of plasma Aβ oligomers in humans.Results: Aβ oligomers were effectively removed by both Membranes A and B. The increase of Aβ oligomers in plasma was observed just after the removal of plasma Aβ oligomers in humans. The intact molecular size of major Aβ oligomers in the plasma was estimated to be larger than albumin at approximately 60 kDa or more. Additionally, the concomitant removal of Aβ monomers and oligomers evoked dissociation of larger Aβ oligomers into smaller ones and monomers.Conclusion: Aβ oligomers were cleared from plasma both in vitro and in human subjects by using hollow-fiber membranes with large pores, indicating that their intact sizes were mostly larger than 60 kDa. Aβ oligomers in peripheral circulation were increased after some clearances in human. Further investigation will determine whether the Aβ oligomers detected in circulation after clearance were via influx from the brain.Keywords: Aβ, amyloid beta, oligomer, Alzheimer’s disease, blood purification, membrane separation |
| format |
article |
| author |
Saito Y Sakata M Kobayakawa M Kawachi H Kawaguchi K Hiki Y Kato M Mori M Hasegawa M Ohashi N Yuzawa Y Kitaguchi N |
| author_facet |
Saito Y Sakata M Kobayakawa M Kawachi H Kawaguchi K Hiki Y Kato M Mori M Hasegawa M Ohashi N Yuzawa Y Kitaguchi N |
| author_sort |
Saito Y |
| title |
Removal of Aβ Oligomers from the Blood: A Potential Therapeutic System for Alzheimer’s Disease |
| title_short |
Removal of Aβ Oligomers from the Blood: A Potential Therapeutic System for Alzheimer’s Disease |
| title_full |
Removal of Aβ Oligomers from the Blood: A Potential Therapeutic System for Alzheimer’s Disease |
| title_fullStr |
Removal of Aβ Oligomers from the Blood: A Potential Therapeutic System for Alzheimer’s Disease |
| title_full_unstemmed |
Removal of Aβ Oligomers from the Blood: A Potential Therapeutic System for Alzheimer’s Disease |
| title_sort |
removal of aβ oligomers from the blood: a potential therapeutic system for alzheimer’s disease |
| publisher |
Dove Medical Press |
| publishDate |
2020 |
| url |
https://doaj.org/article/06a560a2c9e14525a9e3896d39fab4c2 |
| work_keys_str_mv |
AT saitoy removalofabetaoligomersfromthebloodapotentialtherapeuticsystemforalzheimerrsquosdisease AT sakatam removalofabetaoligomersfromthebloodapotentialtherapeuticsystemforalzheimerrsquosdisease AT kobayakawam removalofabetaoligomersfromthebloodapotentialtherapeuticsystemforalzheimerrsquosdisease AT kawachih removalofabetaoligomersfromthebloodapotentialtherapeuticsystemforalzheimerrsquosdisease AT kawaguchik removalofabetaoligomersfromthebloodapotentialtherapeuticsystemforalzheimerrsquosdisease AT hikiy removalofabetaoligomersfromthebloodapotentialtherapeuticsystemforalzheimerrsquosdisease AT katom removalofabetaoligomersfromthebloodapotentialtherapeuticsystemforalzheimerrsquosdisease AT morim removalofabetaoligomersfromthebloodapotentialtherapeuticsystemforalzheimerrsquosdisease AT hasegawam removalofabetaoligomersfromthebloodapotentialtherapeuticsystemforalzheimerrsquosdisease AT ohashin removalofabetaoligomersfromthebloodapotentialtherapeuticsystemforalzheimerrsquosdisease AT yuzaway removalofabetaoligomersfromthebloodapotentialtherapeuticsystemforalzheimerrsquosdisease AT kitaguchin removalofabetaoligomersfromthebloodapotentialtherapeuticsystemforalzheimerrsquosdisease |
| _version_ |
1718398282419404800 |